Skip to content

Embryo Aneuploidies and Ovarian Stimulation

Incidence of EmbyoO Aneuploidies in Natural Versus Stimulated Cycles in the Same Women.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00707525
Enrollment
Unknown
Registered
2008-07-01
Start date
2008-02-29
Completion date
2010-02-28
Last updated
2010-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Embryo Aneuploidies

Keywords

aneuploidies, natural cycle, stimulated cycle, preimplantation genetic diagnosis

Brief summary

There is a considerable concern about the effects of controlled ovarian hyperstimulation (COH) for In Vitro Fertilization- Embryo Transfer (IVF-ET) on embryo quality and on the incidence of chromosomal abnormalities in oocytes and embryos. The main question remaining is if COH may increase the aneuploidies rate in young and healthy women. Therefore, the primary endpoint of the present study is to analyse the incidence of chromosomal abnormalities in this group of patients (oocyte donors), either in oocytes obtained after a natural cycle or in those retrieved after a COH cycle. To get rid of the male factor influence, donated sperm will be used.

Interventions

Preimplantation Genetic Diagnosis (PGD) is performed on the embryos resulting from these natural and stimulated cycles.

Sponsors

Instituto Valenciano de Infertilidad, IVI VALENCIA
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

Donor Inclusion Criteria: * 18 to 35 years old. * BMI: 18-25Kg/m2 * Regular menstrual cycles * Normal kariotype * No previous controlled ovarian hyperstimulation (COH) treatments. Donor

Exclusion criteria

* Endometriosis * Policystic ovarian syndrome * Recurrent miscarriages. Recipient Inclusion Criteria * Aged until 45 years old * No systemic diseases * Following egg and sperm donation treatment. Recipient

Design outcomes

Primary

MeasureTime frame
Embryo aneuploidies2 cycles

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026